▟ Vinebot intrinsic value, daily

← back

SOLV Solventum

healthcare · valued with opus medium conviction · deep-dived 2026-11-12

BUY
Intrinsic value$69.19
Price (at call)$88.62
Margin of safety -21.9%
vs market (rating basis) +15.6%

Separation noise hides a steady 20%-margin healthcare franchise; modest upside if one-offs truly stop.

The story

Solventum is the 3M healthcare spin-off: wound care (MedSurg), dental, and health information systems. These are sticky, mid-single-digit-growth franchises with real brand and installed-base moats, but the company carries meaningful spin-related debt. It is a mature business still working through separation: it is untangling from 3M's IT and supply chain, has sold its filtration unit, and is deleveraging. That process puts noise in reported margins but has not changed the core economics.

I kept the drivers essentially unchanged. The 5.1% TTM margin looks like separation, restructuring and impairment charges, not lost pricing power, because revenue held flat at about $8.2B. Annual margins have still landed at 20-25% outside the charge-heavy year. I trimmed the target margin slightly, from 22.5% to 22%, because the run of one-offs is recurring more than a truly clean spin would. Beta stays at 1.1 to reflect $4.2B of net debt.

Value drivers

Revenue growth (Y1)2.0%
Terminal growth2.5%
Forecast horizon6y
Target operating margin22.0%
Years to target margin4
Sales-to-capital0.85
Beta1.10
Failure probability2.5%
Cost of capital (WACC)10.0%
Terminal WACC9.6%

Valuation bridge

PV of explicit FCFF4.98B
PV of terminal value11.23B
Equity value11.76B
÷ shares → per share$69.19

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 8.33B 2.0% 9.3% 704.99M 192.05M 512.95M 466.49M
2 8.50B 2.1% 13.5% 1.05B 205.68M 840.39M 695.06M
3 8.69B 2.2% 17.8% 1.40B 220.00M 1.18B 889.47M
4 8.89B 2.3% 22.0% 1.78B 235.06M 1.54B 1.05B
5 9.10B 2.4% 22.0% 1.82B 250.92M 1.57B 975.21M
6 9.33B 2.5% 22.0% 1.86B 267.65M 1.60B 903.14M

Key risks

  • 'One-time' separation and restructuring costs keep recurring and permanently cap margins below 20%
  • Wound care faces pricing pressure and competition, and dental demand is cyclical
  • Leverage limits flexibility if exiting 3M's transition-services agreements costs more than planned

Catalysts

  • Clean quarters after the 3M transition-services agreements end show 20%+ operating margins
  • Proceeds from the filtration sale pay down debt, cutting interest costs and equity risk

History

DatePriceIntrinsicMoSRating
2026-11-12$88.62 $69.19 -21.9% BUY
2026-09-23$88.75 $110.73 +24.8% STRONG BUY
2026-08-04$88.07 $112.77 +28.0% STRONG BUY
2026-06-23$73.99 $110.45 +49.3% STRONG BUY